Open AccessPlasma galectin-9 as a predictor of adverse non-AIDS events in persons with chronic HIV during suppressive antiretroviral therapy
Author(s) -
Thomas A. Premeaux,
Carlee Moser,
Ashley McKhann,
Martin Hoenigl,
Elizabeth Laws,
Draven L Aquino,
Michael M. Lederman,
Alan Landay,
Sara Gianella,
Lishomwa C. Ndhlovu
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000003048
Subject(s) - interquartile range , medicine , immunology , odds ratio , myocardial infarction , stroke (engine) , logistic regression , mechanical engineering , engineering
People with HIV (PWH) on antiretroviral therapy (ART) still experience an increased risk of morbidity and mortality, presumably driven by chronic inflammation, yet predictors of discrete or combinatorial outcomes remain unclear. Galectin-9 (Gal-9), a driver of both inflammatory and immunosuppressive responses, has been associated with HIV disease progression and multimorbidity.